New cancer clinical trial: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Published on: January 29, 2019 at 12:00PM
Condition:   Breast Cancer Recurrent
Interventions:   Drug: Palbociclib 125mg;   Drug: Standard endocrine therapy
Sponsors:   International Breast Cancer Study Group;   Pfizer
Not yet recruiting
http://bit.ly/2MEhQGI